Refine by MP, party, committee, province, or result type.

Results 46-60 of 65
Sorted by relevance | Sort by date: newest first / oldest first

Industry committee  Well, in a non-pandemic scenario, they also procure and make decisions about procurement—

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  That is what I understand to be the case, now.

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  All right. Ultimately, we came up with three platforms. There are about five or six that are out there being explored: the adenovirus vector, the protein, the virus-like particle and the mRNA. What we did was look at each stage that you would consider in clinical development. S

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  Mark, do you want to handle that?

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  Providence would have been considered along with all the domestic candidates. A very systematic and similar process was considered for each one. They submitted an application, so we had the application to look at. We had interviews where they came before the committee and made pr

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  Okay. I'm so sorry.

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  I think you're asking whether in my work at the Canadian Center for Vaccinology we had discussions with AstraZeneca. We are certainly very aware of the group at Oxford and collaborate with them, but they were not looking for a partnership with us to do studies—

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  Yes, for every single candidate we considered part of the rubric was the possibility to partner with Canadian scientists, or businesses or government scientists, to make it a value option for Canadians. Every vaccine was considered under that lens.

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  Thank you for the opportunity to clarify that. I would separate quite clearly clinical development and research from choosing vaccines to buy for Canada. We do here at the Canadian Center for Vaccinology at Dalhousie a number of very early vaccine studies. Most of those never ma

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  I can speak to the question about me. Roger, perhaps, could do the second part. You're right that it's very similar to what we do for journals. For every trial that we publish the results for, for every talk that we give, particularly in a university, we have to have a slide tha

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  I can tell you what the disclosure was to the NRC. I listed every possible relationship I would have had to Janssen. Not all of those would have been listed, potentially.

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  No, journals are very different, so you can't make a general statement about journals, I think it would be fair to say.

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  I'm not getting translation, but you related the timelines for the pandemic and asked who made the decision about the task force and who they consulted. I think that would be a question for the secretariat. Would that be correct, Roger?

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  I would say that we looked at all the international candidates on the same shelf. CanSino was one of those international candidates. We were hoping for a domestic candidate and we very much placed equal emphasis on all the domestic candidates, but ultimately our goal was a safe a

February 18th, 2021Committee meeting

Dr. Joanne Langley

Industry committee  There were at least 24 SIF proposals, but there were other ways that support could be accessed. Mark?

February 18th, 2021Committee meeting

Dr. Joanne Langley